Renhuang Showcases its All Natural Products at 45th China National New and Special Drugs Fair

HARBIN, China, July 14 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that Renhuang showcased its range of all-natural, plant-based Botanical, Traditional Chinese Medicines and Biopharmaceutical products at the 45th China National New and Special Drugs Fair 2010 (the "Drug Fair") from July 8th to July 10th.

As one of the most highly publicized and best-attended fairs supported by China's Department of Commerce, the Drug Fair focuses on developing the country's drug market and highlights innovative drug technology. Over 1,000 companies participated in the Drug Fair, and more than 70,000 visitors attended.

Renhuang used the venue to promote its brand name and to introduce its major new products such as Qing Re Jie Du Oral Liquid, a treatment for influenza and upper respiratory illness. Also highlighted were the Company's new Compound Schisandra Tablets, a new plant-based anti-depressant and nerve regulation product, as well as Renhuang's Ginseng and Deer Antler Extract.

"The interest our new products generated at the Drug Fair is, we believe, a testament both to the quality of our pipeline, and to the effectiveness of our marketing program," said Mr. Shaoming Li, the Company's Chairman and Chief Executive Officer. "The Company will continue to market aggressively at these important national fairs, thereby raising our brand recognition and improving our distribution network through new partnerships."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's participation in the 45th China National New and Special Drugs Fair and expected positive outcomes, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For more information, please contact:

    Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Phone: +86-451-8260-2162
     Email: [email protected]

    CCG Investor Relations:
     Mr. Mark Collinson, Partner
     Phone: +1-310-954-1343 (Los Angeles)
     Email: [email protected]
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: [email protected]

SOURCE Renhuang Pharmaceuticals, Inc.